Archives
LY2109761: Selective TβRI/II Kinase Inhibitor for TGF-β P...
LY2109761: Dual TGF-β Receptor Inhibition for Precision Modulation of Cancer and Fibrosis Signaling
Executive Summary: LY2109761 is a small-molecule dual inhibitor of transforming growth factor-beta receptor types I and II (TβRI/II), with Ki values of 38 nM and 300 nM, respectively, and an IC50 of 69 nM for TβRI enzymatic activity (ApexBio). It acts through selective blockade of the ATP-binding site in TGF-β receptor I, preventing downstream phosphorylation of Smad2 and Smad3 transcription factors (Silva et al., 2014). Preclinical studies demonstrate its efficacy in suppressing proliferation, migration, and invasion of pancreatic cancer cells, enhancing radiosensitivity in glioblastoma, and reducing radiation-induced pulmonary fibrosis. The compound is soluble at ≥22.1 mg/mL in DMSO and should be used promptly after solution preparation to maintain activity (ApexBio). LY2109761 is widely used in studies of TGF-β signaling, apoptosis induction, and cancer metastasis inhibition.
Biological Rationale
The transforming growth factor-beta (TGF-β) pathway is a central regulator of cell proliferation, differentiation, and apoptosis in mammalian tissues (Silva et al., 2014). Canonical TGF-β signaling is mediated by the sequential activation of TGF-β receptor II (TβRII) and TGF-β receptor I (TβRI), leading to phosphorylation of Smad2/3 and transcriptional regulation of cell cycle genes. In mammary epithelial cells, this pathway enforces cytostatic effects by upregulating CDK inhibitor P15INK4B and downregulating CDC25A and MYC, thereby arresting the G1/S cell cycle transition (Silva et al., 2014). Aberrant TGF-β signaling contributes to tumor progression, metastasis, and therapy resistance. Dual inhibition of TβRI/II is a validated strategy to dissect these roles and overcome resistance mechanisms in cancer and fibrotic disorders.
Mechanism of Action of LY2109761
LY2109761 is a selective, ATP-competitive inhibitor that targets both TβRI and TβRII kinases. The compound binds the ATP-binding site of the TGF-β receptor I kinase domain, blocking autophosphorylation and subsequent activation of downstream effectors. Its inhibition constants (Ki) are 38 nM for TβRI and 300 nM for TβRII, with an IC50 of 69 nM for TβRI in enzymatic assays (ApexBio). LY2109761 effectively suppresses phosphorylation of Smad2 and Smad3, key intermediates in canonical TGF-β signaling, thereby inhibiting downstream transcriptional programs involved in proliferation, survival, and EMT (epithelial-mesenchymal transition) (Silva et al., 2014). Off-target inhibition of kinases such as Lck, Sapk2α, MKK6, Fyn, and JNK3 occurs only at higher, non-physiological concentrations.
Evidence & Benchmarks
- LY2109761 exhibits sub-100 nM potency for TβRI inhibition in enzymatic assays (IC50 = 69 nM; DMSO vehicle, 25°C) (ApexBio).
- In preclinical pancreatic cancer models, LY2109761 suppresses cell proliferation, migration, and invasion in vitro and in vivo (ApexBio).
- LY2109761 enhances radiosensitivity in glioblastoma cell lines, resulting in improved cell killing upon irradiation (ApexBio).
- Administration of LY2109761 reduces radiation-induced pulmonary fibrosis in animal models (ApexBio).
- LY2109761 disrupts Smad2/3 phosphorylation and downstream TGF-β1-induced gene expression, as confirmed by Western blot and transcriptomic analyses (Silva et al., 2014).
- The compound reverses the anti-apoptotic effects of TGF-β1 in myelo-monocytic leukemic cells (ApexBio).
This article extends prior work (LY2109761: Dual TGF-β Receptor Inhibitor in Smad2/3-Driven Disorders) by providing additional quantitative benchmarks and clarifying boundaries of specificity in off-target kinase inhibition.
For a deeper mechanistic outlook, see Precision Disruption of TGF-β Signaling: Strategic Guidance, which focuses on translational research applications, while the current review emphasizes in vitro/in vivo potency and workflow integration.
Applications, Limits & Misconceptions
LY2109761 is widely used as a research tool in oncology, fibrosis, and cell signaling studies. Its dual inhibition profile allows precise modulation of canonical TGF-β signaling. Typical applications include:
- Inhibition of cancer cell proliferation, migration, and invasion, especially in pancreatic and glioblastoma models (ApexBio).
- Suppression of Smad2/3 phosphorylation for mechanistic dissection of TGF-β pathway roles (Silva et al., 2014).
- Reduction of radiation-induced pulmonary fibrosis in preclinical settings (ApexBio).
- Reversal of TGF-β1-mediated anti-apoptotic effects in leukemic cells.
Related discussion of experimental precision and selectivity is available in LY2109761: Selective TβRI/II Kinase Inhibitor for Precision Research, which this article updates with recent evidence and new workflow parameters.
Common Pitfalls or Misconceptions
- LY2109761 is not effective against non-canonical TGF-β signaling branches (e.g., MAPK, PI3K/AKT pathways).
- Ineffective in cell types where TGF-β signaling is Smad-independent or redundant.
- Off-target kinase inhibition (Lck, Fyn, JNK3) is negligible at recommended concentrations; inhibition at higher doses is not selective.
- Compound is insoluble in water and ethanol; improper solvent use leads to precipitation and loss of activity.
- Prolonged solution storage (even in DMSO) reduces potency; use freshly prepared solutions.
Workflow Integration & Parameters
LY2109761 is supplied as a solid and should be stored at -20°C. It is readily soluble at concentrations ≥22.1 mg/mL in DMSO but insoluble in water and ethanol (ApexBio). For cell-based assays, DMSO stock solutions are recommended to be freshly prepared and diluted into culture medium immediately before use to maintain compound integrity. Typical working concentrations range from 10 nM to 1 μM, depending on experimental design and cell type. Application protocols should include solvent controls and verification of Smad2/3 phosphorylation blockade by Western blot or equivalent assays.
For detailed experimental design and comparative performance, refer to the LY2109761 product page and recent review articles.
Conclusion & Outlook
LY2109761 remains a reference-standard dual TGF-β receptor inhibitor for dissecting canonical pathway functions in cancer, fibrosis, and cell signaling research. Its selectivity, potency, and validated benchmark data support continued use in mechanistic and translational studies. Future research will benefit from combining LY2109761 with genetic or alternative pharmacological tools to map context-specific TGF-β responses and resistance mechanisms.